for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  PharmAsia News
  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [13 journals]
  • Mixed Results For Japan Pharma In Reputational Survey
    • Abstract: Out of the multinational pharma companies covered by a new survey of corporate reputation among international patients' groups, some of those in Japan fared well - while other majors have some work to do.
      PubDate: Fri, 27 Feb 2015 01:55:01 -050
       
  • Emerging Markets Regulatory Tracker: India Cracks Down On False Data
    • Abstract: India’s CDSCO is taking steps to crack down on the submission of falsified data to support product approvals.
      PubDate: Fri, 27 Feb 2015 01:35:01 -050
       
  • BioAsia 2015: Fixes To India’s Medicines Access Issue
    • Abstract: Access to medicines is a hot button topic in India. The government has spoken on interventions like establishing low cost generic drug stores, while the industry is toying with financing models to improve treatment rates.
      PubDate: Thu, 26 Feb 2015 18:05:02 -050
       
  • Counterfeits Seized, Syrian Dimension Unveiled In Turkish Raids
    • Abstract: Illegal activities to sell counterfeit medicines in Turkey continue unabated despite efforts to marginalize and eliminate such products. In demand cancer and transplantation drugs in particular are becoming the means for profitable sales for some criminal networks.
      PubDate: Thu, 26 Feb 2015 18:00:02 -050
       
  • Olmesartan Expiry In Mind As Daiichi Sankyo Shakes Up
    • Abstract: Major Japanese firm Daiichi Sankyo has unveiled a fundamental shakeup across its corporate structure that will see a cut in the number of divisions and simplification of reporting lines, as it battens down and cuts costs ahead of olmesartan's loss of exclusivity.
      PubDate: Thu, 26 Feb 2015 01:25:00 -050
       
  • INTERVIEW: Dr. Reddy’s CEO On Move From Curing Diseases To Managing
           Health (Part 2 of 2)
    • Abstract: G.V. Prasad, the CEO of Dr.
      PubDate: Wed, 25 Feb 2015 18:30:00 -050
       
  • Multinationals Look To M&A As Key China Growth Driver
    • Abstract: Mergers and acquisitions have been highlighted as key drivers of growth for pharma companies in China as domestic companies look to expand globally and multinationals attempt to localize.
      PubDate: Wed, 25 Feb 2015 18:25:01 -050
       
  • Proposed China GCPs To Bolster Local Clinical Trial Supervision
    • Abstract: The China Food and Drug Administration is seeking to revise the country's good clinical practices (GCPs) for drug trials for the first time in around 12 years.
      PubDate: Wed, 25 Feb 2015 03:25:02 -050
       
  • New Takeda Moves Signal Emerging Markets Intent
    • Abstract: Takeda is sending out renewed signals of its commitment to expansion in Asia and other emerging markets through new steps in Turkey and Singapore to expand its commercial presence and other capabilities.
      PubDate: Wed, 25 Feb 2015 01:50:00 -050
       
  • South Korea Launches Second Pharma Development Fund
    • Abstract: South Korea’s Ministry of Health and Welfare is launching its second ‘Global Pharma Industry Development Fund’ worth KRW135 billion ($124 million) to help small and mid-sized local firms with cooperative technology development, deals with foreign venture firms, sales networks and production facilities in foreign countries, and global clinical trials.
      PubDate: Tue, 24 Feb 2015 20:35:01 -050
       
  • Boehringer Ingelheim: Balancing Innovation And Affordable Pricing In India
    • Abstract: Over the last five years, Boehringer Ingelheim has stayed aggressive on India. It continues to be so and in a signal of further optimism its global chairman Andreas Barner outlined in a discussion with PharmAsia News more new plans that will fuel growth, including weighing financing models to bring oncology medicines to a wider income strata.
      PubDate: Tue, 24 Feb 2015 18:30:01 -050
       
  • $400m Heptares Acquisition To Drive Sosei’s R&D
    • Abstract: Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.
      PubDate: Mon, 23 Feb 2015 20:35:01 -050
       
  • Turkey Company Roundup: New Appointments, Big Ambitions
    • Abstract: Changes have taken place at the senior level in Novartis and Sanofi in Turkey, two big players in the local market, while domestic firm Pharmactive is aiming for a top five position by 2018.
      PubDate: Mon, 23 Feb 2015 02:00:01 -050
       
  • Zelboraf, Cosentyx and Takecab Set For Japan Listing, Launch
    • Abstract: Japan's granting of reimbursement prices to a batch of new drugs including Chugai's Zelboraf for melanoma, Novartis's Cosentyx for psoriasis and Takeda's gastrointestinal P-CAB inhibitor Takecab clears the way for the products’ commercial launch in the country.
      PubDate: Mon, 23 Feb 2015 01:55:01 -050
       
  • Emerging Markets Regulatory Tracker: India Expanding Tamiflu Access
    • Abstract: India is taking steps to expand access to the antiviral drug Tamiflu to cope with a rising number of swine flu cases.
      PubDate: Thu, 19 Feb 2015 20:20:01 -050
       
  • Cynata Surges On Stem Cell Production Breakthrough
    • Abstract: Shares in Melbourne-based stem cell manufacturer Cynata Therapeutics more than doubled on the Australian Securities Exchange (ASX) on Feb.19 after emerging from a 48-hour trading halt, as the company announced that its “world-first” production technology had passed a critical test in the U.S.
      PubDate: Thu, 19 Feb 2015 19:35:01 -050
       
  • American Pharma Sees Worsening China Investment Climate
    • Abstract: One third of correspondents from R&D-intensive industries including pharma see the investment environment worsening in China, citing labor costs and inconsistent regulation. Addressing the challenges, more than 70% are proactively hiring local Chinese for key executive positions, says a just released China business climate survey.
      PubDate: Wed, 18 Feb 2015 23:30:01 -050
       
  • PhRMA Spies Opportunities Amid ‘Remarkable’ Japan Improvements
    • Abstract: The U.S. industry association PhRMA has described as "remarkable" the continuing improvements in the performance of Japan's regulatory agency, the PMDA, but still would like to see further progress in drug pricing and other reforms.
      PubDate: Wed, 18 Feb 2015 18:30:00 -050
       
  • Two Kalbe Drugs Withdrawn In Indonesia After Deaths
    • Abstract: Kalbe Farma, Indonesia’s largest pharmaceutical company, has withdrawn two prescription drugs following the deaths of two patients at a hospital, the company said.
      PubDate: Wed, 18 Feb 2015 18:25:04 -050
       
  • INTERVIEW: Dr. Reddy’s CEO On Move From Curing Diseases To Managing
           Health (Part 1 of 2)
    • Abstract: G.V. Prasad, the CEO of Dr.
      PubDate: Wed, 18 Feb 2015 18:20:00 -050
       
  • Last Hopes Fade For Takeda’s Motesanib
    • Abstract: Takeda's hope that its investigational multi-targeted anticancer motesanib would succeed in Asian non-small cell lung cancer (NSCLC) patients where it failed in other populations has been dashed after it missed the primary endpoint in the Phase III MONET-A trial.
      PubDate: Tue, 17 Feb 2015 20:20:01 -050
       
  • Big Deal Brewing At India’s Claris: Sell-off Or JV'
    • Abstract: After Agila, which was acquired by Mylan in 2013, Claris, another Indian injectables business, is reported to be on the block. Some in the industry believe if not an outright sell-off, the deal may take the form of a broad-focused global joint venture.
      PubDate: Tue, 17 Feb 2015 18:25:03 -050
       
  • China Dominates Novo Nordisk’s Emerging Markets
    • Abstract: As far as Novo Nordisk's emerging markets business was concerned last year, it was all about China, with the country providing an important source of corporate growth and offering attractive future opportunities.
      PubDate: Tue, 17 Feb 2015 18:20:00 -050
       
  • First Approval for Eisai’s Lenvatinib, In U.S
    • Abstract: Eisai gained U.S. approval on Feb.13 for Lenvima (lenvatinib) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, or RAI-R DTC, marking the first clearance worldwide for the oral tyrosine kinase inhibitor. The Japanese firm also gained a U.S. approval for an additional pediatric indication for its epilepsy drug Banzel (rufinamide).
      PubDate: Mon, 16 Feb 2015 23:35:01 -050
       
  • New Law To End India’s Tryst With Fixed Dose Combos'
    • Abstract: A recent study by international scientific journal The Lancet has slammed Indian drug regulatory agencies for approving fixed dose combinations that are not backed by robust clinical trial data. The government, for its part, says the solution is in a proposed new set of laws that is under active discussions.
      PubDate: Mon, 16 Feb 2015 18:20:01 -050
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014